A recent study indicates that individuals who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who halt conventional diet and exercise regimens.
Published data in a prominent medical journal points out that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing such drugs should be aware of the risk of fast weight regain when the treatment ends," cautioned expert Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight in about a year and a half.
Comparing Treatments
The analysis, which examined 37 of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that individuals who lose weight through dieting generally experience a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts propose the mode of action of the jabs is key to understanding the accelerated weight return.
These medications mimic a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
A Chronic Condition?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of relapse, the therapy should be considered ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "emphasize the persistent nature of obesity," comparing it to managing diseases like diabetes.
User Experiences
Individuals who have stopped the medication describe a sudden return of appetite.
"It was like something that goes on and I was suddenly extremely hungry," recalled a patient.
The struggle is worsened if users have not established lasting dietary or behavioural changes during treatment.
Widespread Adoption
Figures show that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Use is greater among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on ongoing lifestyle support.
